Pharmaceutical

Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual CAR-T therapies will yield sales of USD 1 billion, the investing companies hope to rope in higher sales. With the death of five patients in the trials of Juno Therapeutics, Seattle Biotech now assumes its CAR-T cell therapy to be the best in class. While the equipment makers are now independent and are making their own inventions in CAR-T cell therapy, bigger companies are also getting involved in this business like GE Healthcare ...